Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B study 8662 Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Receptor, ErbB-2

abstract

  • ECD/HER-2 levels are elevated in 35-40% of patients with metastatic breast cancer. Elevated ECD/HER-2 levels are associated with a poorer prognosis in these patients. However, no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.

publication date

  • January 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11555582

Additional Document Info

start page

  • 2703

end page

  • 11

volume

  • 7

number

  • 9